• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

November 13, 2013: Vaccines and Related Biological Products Advisory Committee Meeting Draft Agenda

Food and Drug Administration
Center for Biologics Evaluation and Research
Vaccines and Related Biological Products Advisory Committee
134th Meeting via Teleconference
Rockwall II, Conference Room 1033
5515 Security Lane, Rockville, MD
November 13, 2013

DRAFT AGENDA

Agenda Open Session
12:30 p.m. Call to Order and Opening Remarks
Robert Daum, M.D., Chair

Conflict of Interest Statement
Donald Jehn, M.S., FDA
12:40 p.m. Acknowledgement of Retiring Members
Marion Gruber, Ph.D., FDA
Topic I

Presentation of Laboratory of Retroviruses and Laboratory of Immunoregulation, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research
12:50 Overview of Research/Site Visit Process,
Center Biologics Evaluation and Research (CBER)
Carolyn Wilson, Ph.D., FDA 
1:10 Overview Division of Viral Products, OVRR
Jerry Weir, Ph.D., FDA
1:25 Overview Laboratory of Retroviruses
Hana Golding, Ph.D., FDA
1:50 Overview Laboratory of Immunoregulation
Carol Weiss, MD, Ph.D., FDA
2:10 Open Public Hearing (if no speakers, will move directly to closed session)
3:10 Closed Session
3:45 Adjourn Meeting